PYC Therapeutics Ltd traded at 1.60 this Friday January 30th, decreasing 0.02 or 1.23 percent since the previous trading session. Looking back, over the last four weeks, PYC Therapeutics lost 3.32 percent. Over the last 12 months, its price rose by 31.15 percent. Looking ahead, we forecast PYC Therapeutics Ltd to be priced at 1.57 by the end of this quarter and at 1.47 in one year, according to Trading Economics global macro models projections and analysts expectations.
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company''s VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.